Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Zetia

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Zetia was produced by Merck & Co. and Bayer.

PCSK9 inhibitor alirocumab works in statin-intolerance

PCSK9 inhibitor alirocumab works in statin-intolerance Sanofi and Regeneron’s drug impresses at American Heart Association meeting. Sanofi and Regeneron's investigational drug alirocumab is more effective at reducing cholesterol levels than Merck &Co's Zetia in ... results of the IMPROVE-IT trial have now

Merck's ezetimibe has 'modest' benefit when added to statins

Merck's ezetimibe has 'modest' benefit when added to statins Vytorin and ezetimibe monotherapy Zetia got off to a strong start in the market but were quickly enveloped in controversy when the results of another study - called ENHANCE - failed to show ... Undeterred, Merck has said it will now file for approval of

Sanofi and Regeneron pay $67.5m to speed alirocumab review

Sanofi and Regeneron pay $67.5m to speed alirocumab review phase III trials, outperforming rival drug Zetia (ezetimibe) from Merck &Co as a monotherapy.  .

Amgen cholesterol antibody shines in rare disease trial

Amgen cholesterol antibody shines in rare disease trial At the moment, patients are typically treated with a combination of statins, Merck &Co's Zetia (ezetimibe) and other cholesterol-lowering drugs such as niacin, with limited efficacy.

FDA scrutiny of alirocumab hits Regeneron and Sanofi

FDA scrutiny of alirocumab hits Regeneron and Sanofi Alirocumab (also known as REGN727) has shown very positive activity in phase III trials reported to date, outperforming rival drug Zetia (ezetimibe) from Merck &Co as a monotherapy.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics